ViraCyte Receives $8.99M Grant from the Cancer Prevention and Research Institute of Texas

ViraCyte, LLC, a Houston, TX-based clinical stage biopharmaceutical company developing cellular immunotherapies for severe viral infections, is to receive a Product Development Research grant totaling $8.99m.

The Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee will support the clinical development of the company’s lead product, Viralym-M – a “ready to administer” multivirus-specific T cell immunotherapy.
Pending negotiations and contract execution, the CPRIT award, entitled Improving Outcome of Stem Cell Transplants for Cancer Treatment Using Multi-Virus Specific T cells, will support an advanced clinical trial testing the safety and efficacy of Viralym-M in adult and pediatric cancer patients.

ViraCyte provides products that restore natural immunity against life threatening viruses in patients with severely weakened immune systems, such as adults and children who have recently undergone a hematopoietic stem cell transplant (HSCT).
Its lead T cell products are in Phase 2 and Phase 1 clinical trials.
ViraCyte is a resident company at JLABS @ TMC, Houston, Texas.

Join the discussion